Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
RESEARCH TOOLSreports
GPCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.22 - $53.45
Previous CloseN/A
Volume219.80K
Average Volume (3M)786.86K
Market Cap
$1.26B
Enterprise Value$11.32B
Total Cash (Recent Filing)$836.88M
Total Debt (Recent Filing)$7.59M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 07, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding57,536,750
10 Day Avg. Volume955,065
30 Day Avg. Volume786,863
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-99.14
Price to Sales (P/S)0.00
P/FCF Ratio-246.69
Enterprise Value/Market Cap9.02
Enterprise Value/Revenue4.26K
Enterprise Value/Gross Profit-48.87K
Enterprise Value/Ebitda-18.81
Forecast
1Y Price Target
$78.56Price Target Upside245.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Structure Therapeutics, Inc. Sponsored ADR News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company has a catalyst-rich period ahead with key data readouts from several small molecule compositions, including two Phase 2b readouts in the last quarter and the start of amylin FIH by year-end.
Market PositionPfizer discontinuing development of their oral small molecule GLP-1R agonist, danuglipron, reduces near-term competition for aleniglipron.
Safety And TolerabilityThe company believes that safety and tolerability will improve with a 'start low, go slow' strategy, as seen in previous trials, which could lead to better outcomes.
Bears Say
Market CompetitionPharmacy benefit manager (PBM) access remains a challenge for incremental entrants in this space.
Product PositioningAn important consideration for oral obesity treatments is how Lilly will position orforglipron alongside tirzepatide and whether oral GLP-1 therapies can carve out a meaningful role given the entrenched dominance of injectable formulations.
Ownership Overview
11.67% Insiders
35.25% Mutual Funds
43.64% Other Institutional Investors
8.43% Public Companies and Individual Investors
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $53.45 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $1.26B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Aug 07, 2025 which is in 55 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on May 08, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.241 by -$0.029.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.27.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 57,536,750 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.241. Following the earnings report the stock price went down -4.661%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.56 (245.77% Upside)
$78.56 (245.77% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 993.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.59%
12-Months-Change
Fundamentals
Return on Equity
-22.88%
Trailing 12-Months
Asset Growth
89.53%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics, Inc. Sponsored ADR (GPCR) is a biopharmaceutical company focused on discovering and developing innovative treatments for patients with unmet medical needs. The company primarily operates within the healthcare sector, specializing in the development of novel drug candidates targeting G protein-coupled receptors (GPCRs), which play a crucial role in various physiological processes and diseases. Structure Therapeutics leverages advanced technologies and scientific expertise to design and develop therapeutic compounds aimed at addressing conditions such as metabolic disorders, inflammation, and other significant health challenges.
GPCR Stock 12 Month Forecast
Average Price Target
$78.56
▲(245.77%Upside)
Technical Analysis
Wave Life Sciences
―
89bio
―
Enliven Therapeutics
―
Nurix Therapeutics
―
Dyne Therapeutics
―